These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 26791134)

  • 1. Editorial: Ubiquitin E3 Ligases as Molecular Targets or Tools for Advanced Cancer Therapy.
    Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):100. PubMed ID: 26791134
    [No Abstract]   [Full Text] [Related]  

  • 2. The SCF-type E3 Ubiquitin Ligases as Cancer Targets.
    Kitagawa K; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):119-29. PubMed ID: 26560120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
    Masumoto K; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):130-5. PubMed ID: 26560119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer.
    Uchida C; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):157-74. PubMed ID: 26560116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of E3 ubiquitin ligases in gastric cancer.
    Hou YC; Deng JY
    World J Gastroenterol; 2015 Jan; 21(3):786-93. PubMed ID: 25624711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skp1: Implications in cancer and SCF-oriented anti-cancer drug discovery.
    Hussain M; Lu Y; Liu YQ; Su K; Zhang J; Liu J; Zhou GB
    Pharmacol Res; 2016 Sep; 111():34-42. PubMed ID: 27238229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of different E3 ubiquitin ligases in regulation of the P53 tumor suppressor protein].
    Daks AA; Melino D; Barlev NA
    Tsitologiia; 2013; 55(10):673-87. PubMed ID: 25509121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma.
    Bielskienė K; Bagdonienė L; Mozūraitienė J; Kazbarienė B; Janulionis E
    Medicina (Kaunas); 2015; 51(1):1-9. PubMed ID: 25744769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NEDD4: a promising target for cancer therapy.
    Ye X; Wang L; Shang B; Wang Z; Wei W
    Curr Cancer Drug Targets; 2014; 14(6):549-56. PubMed ID: 25088038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The application of ubiquitin ligases in the PROTAC drug design.
    Chen Y; Jin J
    Acta Biochim Biophys Sin (Shanghai); 2020 Jul; 52(7):776-790. PubMed ID: 32506133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E3 ubiquitin ligases in cancer and implications for therapies.
    Wang D; Ma L; Wang B; Liu J; Wei W
    Cancer Metastasis Rev; 2017 Dec; 36(4):683-702. PubMed ID: 29043469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of Epithelial-Mesenchymal Transition by E3 Ubiquitin Ligases and Deubiquitinase in Cancer.
    Inoue Y; Itoh Y; Sato K; Kawasaki F; Sumita C; Tanaka T; Morishita D; Hayashi H
    Curr Cancer Drug Targets; 2016; 16(2):110-8. PubMed ID: 26560121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted protein degradation: expanding the toolbox.
    Schapira M; Calabrese MF; Bullock AN; Crews CM
    Nat Rev Drug Discov; 2019 Dec; 18(12):949-963. PubMed ID: 31666732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional significance and therapeutic implication of ring-type E3 ligases in colorectal cancer.
    Liu L; Wong CC; Gong B; Yu J
    Oncogene; 2018 Jan; 37(2):148-159. PubMed ID: 28925398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugging the undruggable: targeting challenging E3 ligases for personalized medicine.
    Galdeano C
    Future Med Chem; 2017 Mar; 9(4):347-350. PubMed ID: 28263082
    [No Abstract]   [Full Text] [Related]  

  • 16. Biological influence of Hakai in cancer: a 10-year review.
    Aparicio LA; Valladares M; Blanco M; Alonso G; Figueroa A
    Cancer Metastasis Rev; 2012 Jun; 31(1-2):375-86. PubMed ID: 22349934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial overview: cancer: from target discovery to targeted therapy: the risky business of target validation.
    Cruzalegui F
    Curr Opin Pharmacol; 2014 Aug; 17():iv-vi. PubMed ID: 25220882
    [No Abstract]   [Full Text] [Related]  

  • 18. Ubiquitin Drug Discovery and Diagnostics Conference - targeting E3 ligases.
    Johnston JA
    IDrugs; 2010 Oct; 13(10):695-7. PubMed ID: 20878590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkin: A targetable linchpin in human malignancies.
    Perwez A; Wahabi K; Rizvi MA
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188533. PubMed ID: 33785381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting neddylation in cancer therapy.
    Duncan K; Schäfer G; Vava A; Parker MI; Zerbini LF
    Future Oncol; 2012 Nov; 8(11):1461-70. PubMed ID: 23148618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.